Molecular biology of erythropoietin

Internal Medicine

Volumn 43, Issue 8, 2004, Pages 649-659

  Jelkmann, Wolfgang ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Anemia; Erythropoietin; Hypoxia inducible factor; Kidneys; Recombinant drugs; Red blood cells

Indexed keywords

2 OXOGLUTARIC ACID; ANTINEOPLASTIC AGENT; ASPARAGINE DERIVATIVE; DIMER; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FERROUS ION; GLYCOPROTEIN; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; N(G) METHYLARGININE; NEUROPROTECTIVE AGENT; OXYGEN; OXYGENASE; PLACEBO; PROLINE DERIVATIVE; PROTEIN BCL XL; PROTEIN KINASE; RECOMBINANT ERYTHROPOIETIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 2; TUMOR NECROSIS FACTOR ALPHA; TYROSINE;

ALPHA CHAIN; ANEMIA; APOPTOSIS; BETA CHAIN; CELL VIABILITY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVATION; ERYTHROCYTE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEMATOPOIETIC TISSUE; HORMONE SYNTHESIS; HUMAN; HYDROXYLATION; KIDNEY; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; SURVIVAL TIME; SYSTEMIC CIRCULATION; TUMOR CELL;

ANEMIA; DNA-BINDING PROTEINS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; GENE EXPRESSION REGULATION; HEMATINICS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 4644283464     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.649     Document Type: Review

References (197)

1. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem 252: 5558-5564, 1977.
2. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313: 806-810, 1985.
3. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 82: 7580-7584, 1985.
4. Egrie JC, Strickland TW, Lane J, et al. Characterization and biological effects of recombinant human erythropoietin. Immunobiology 172: 213-224, 1986.
5. Inoue N, Takeuchi M, Ohashi H, Suzuki T. The production of recombinant human erythropoietin. Biotechnol Annu Rev 1: 297-313, 1995.
6. Wen D, Boissel JP, Showers M, Ruch BC, Bunn HF. Erythropoietin structure-function relationships. Identification of functionally important domains. J Biol Chem 269: 22839-22846, 1994.
7. Elliott S, Lorenzini T, Chang D, Barzilay J, Delorme E. Mapping of the active site of recombinant human erythropoietin. Blood 89: 493-502, 1997.
8. Davis JM, Arakawa T, Strickland TW, Yphantis DA. Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 26: 2633-2638, 1987.
9. Imai N, Kawamura A, Higuchi M, Oh-eda M, Orita T, Kawaguchi T, Ochi N. Physicochemical and biological comparison of recombinant human erythropoietin with human urinary erythropoietin. J Biochem (Tokyo) 107: 352-359, 1990.
10. Dordal MS, Wang FF, Goldwasser E. The role of carbohydrate in erythropoietin action. Endocrinology 116: 2293-2299, 1985.
11. Sasaki H, Bothner B, Dell A, Fukuda M. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem 262: 12059-12076, 1987.
12. Sasaki H, Ochi N, Dell A, Fukuda M. Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry. Biochemistry 27: 8618-8626, 1988.
13. Rush RS, Derby PL, Smith DM, Merry C, Rogers G, Rohde MF, Katta V. Microheterogeneity of erythropoietin carbohydrate structure. Anal Chem 67: 1442-1452, 1995.
14. Takeuchi M, Inoue N, Strickland TW, et al. Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. Proc Natl Acad Sci USA 86: 7819-7822, 1989.
15. Misaizu T, Matsuki S, Strickland TW, Takeuchi M, Kobata A, Takasaki S. Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin. Blood 86: 4097-4104, 1995.
16. Takeuchi M, Takasaki S, Shimada M, Kobata A. Role of sugar chains in the in vitro biological activity of human erythropoietin produced in recombinant Chinese hamster ovary cell. J Biol Chem 265: 12127-12130, 1990.
17. Wasley LC, Timony G, Murtha P, et al. The importance of N- and O-linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin. Blood 77: 2624-2632, 1991.
18. Storring PL, Tiplady RJ, Gaines-Das RE, Rafferty B, Mistry YG. Lectin-binding assays for the isoforms of human erythropoietin: comparison of urinary and four recombinant erythropoietins. J Endocrinol 150: 401-412, 1996.
19. Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 98: 3626-3634, 2001.
20. Lasne F, de Ceaurriz J. Recombinant erythropoietin in urine. Nature 405: 635, 2000.
21. Powell JS, Berkner KL, Lebo RV, Adamson JW. Human erythropoietin gene: high level expression in stably transfected mammalian cells and chromosome localization. Proc Natl Acad Sci USA 83: 6465-6469, 1986.
22. Tsuda E, Goto M, Murakami A, et al. Comparative structural study of N-linked oligosaccharides of urinary and recombinant erythropoietins. Biochemistry 27: 5646-5654, 1988.
23. Fibi MR, Hermentin P, Pauly JU, Lauffer L, Zettlmeissl G. N- and O-glycosylation muteins of recombinant human erythropoietin secreted from BHK-21 cells. Blood 85: 1229-1236, 1995.
24. Acharya VN, Sinha DK, Almeida AF, Pathare AV. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis. J Assoc Physicians India 43: 539-542, 1995.
25. Bren A, Kandus A, Varl J, et al. A comparison between epoetin omega and epoetin alfa in the correction of anemia in hemodialysis patients: a prospective, controlled crossover study. Artif Organs 26: 91-97, 2002.
26. Sikole A, Spasovski G, Zafirov D, Polenakovic M. Epoetin omega for treatment of anemia in maintenance hemodialysis patients. Clin Nephrol 57: 237-245, 2002.
27. Kawasaki N, Haishima Y, Ohta M, et al. Structural analysis of sulfated N-linked oligosaccarides in erythropoietin. Glycobiology 11: 1043-1049, 2001.
28. Cointe D, Beliard R, Jorieux S, et al. Unusual N-glycosylation of a recombinant human erythropoietin expressed in a human lymphoblastoid cell line does not alter its biological properties. Glycobiology 10: 511-519, 2000.
29. Delorme E, Lorenzini T, Giffin J, et al. Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry 31: 9871-9876, 1992.
30. Elliott S, Bartley T, Delorme E, et al. Structural requirements for addition of O-linked carbohydrate to recombinant erythropoietin. Biochemistry 33: 11237-11245, 1994.
31. Kitagawa Y, Sano Y, Ueda M, et al. N-glycosylation of erythropoietin is critical for apical secretion by Madin-Darby canine kidney cells. Exp Cell Res 213: 449-457, 1994.
32. Terashima S, Kamihira M, Ogawa T, Ohno M, Iijima S, Kobayashi T. Continuous production of human erythropoietin by immobilized recombinant L-929 cells. Journal of Fermentation and Bioengineering 77: 52-56, 1994.
33. Hayakawa T, Wada M, Mizuno K, Abe S, Miyashita M, Ueda M. In vivo biological activities of recombinant human erythropoietin analogues produced by CHO cells, BHK cells and C127 cells. Biologicals 20: 253-257, 1992.
34. Weikert S, Papac D, Briggs J, et al. Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nature Biotechnol 17: 1116-1121, 1999.
35. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84: 3-10, 2001.
36. Annable L, Cotes PM, Mussett MV. The second international reference preparation of erythropoietin, human, urinary, for bioassay. Bull World Health Organ 47: 99-112, 1972.
37. Storring PL, Gaines Das RE. The International Standard for Recombinant DNA-derived Erythropoietin: collaborative study of four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins. J Endocrinol 134: 459-484, 1992.
38. Jelkmann W, The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombi- nant drugs rhEpo and NESP. Eur J Haematol 69: 265-274, 2002.
39. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 60: 741-747, 2001.
40. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 87: 268-276, 2002.
41. Bachmann S, Le Hir M, Eckardt KU. Co-localization of erythropoietin mRNA and ecto-5′-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 41: 335-341, 1993.
42. Maxwell PH, Osmond MK, Pugh CW, et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 44: 1149-1162, 1993.
43. Maxwell PH, Ferguson DJ, Nicholls LG, et al. Sites of erythropoietin production. Kidney Int 51: 393-401, 1997.
44. Dame C, Sola MC, Lim K-C, et al. Hepatic erythropoietin gene regulation by GATA-4. J Biol Chem 279: 2955-2961, 2004.
45. Tan CC, Eckardt KU, Firth JD, Ratcliffe PJ. Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am J Physiol 263: F474-F481, 1992.
46. Fandrey J, Bunn HF. In vivo and in vitro regulation of erythropoietin mRNA: measurement by competitive polymerase chain reaction. Blood 81: 617-623, 1993.
47. Sasaki R. Pleiotropic functions of erythropoietin. Intern Med 42: 142-149, 2003.
48. Chong ZZ, Kang JQ, Maiese K. Erythropoietin: cytoprotection in vascular and neuronal cells. Curr Drug Targets Cardiovasc Haematol Disord 3: 141-154, 2003.
49. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 72: 449-489, 1992.
50. Jelkmann W. Biochemistry and assays of Epo, in Jelkmann W (ed): Erythropoietin: Molecular Biology and Clinical Use, chap 2. Johnson City, TN, USA, 2003: 35-63.
51. Sherwood JB, Carmichael LD, Goldwasser E. The heterogeneity of circulating human serum erythropoietin. Endocrinology 122: 1472-1477, 1988.
52. Sohmiya M, Kato Y. Molecular and electrical heterogeneity of circulating human erythropoietin measured by sensitive enzyme immunoassay. Eur J Clin Invest 30: 344-349, 2000.
53. Wide L, Bengtsson C, Birgegard G. Circadian rhythm of erythropoietin in human serum. Br J Haematol 72: 85-90, 1989.
54. Macdougall L, Bailon P, Tare N, Pahlke W, Pill J, Brandt M. CERA (Continuous Erythropoiesis Receptor Activator) for the treatment of renal anemia: an innovative agent with unique receptor binding characteristics and prolonged serum half-life. J Am Soc Nephrol 14: 769A, 2003.
55. 2-regulated gene expression. FASEB J 16: 1151-1162, 2002.
56. Ratcliffe PJ. From erythropoietin to oxygen: hypoxia-inducible factor hydroxylases and the hypoxia signal pathway. Blood Purif 20: 445-454, 2002.
57. Gao N, Ding M, Zheng JZ, et al. Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J Biol Chem 277: 31963-31971, 2002.
58. Fandrey J. Regulation of erythropoietin gene expression-understanding cellular oxygen sensing. Am J Physiol 286: R977-R988, 2004.
59. Metzen E, Ratcliffe PJ. HIF hydroxylation and cellular oxygen sensing. Biol Chem 385: 223-230, 2004.
60. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90: 4304-4308, 1993.
61. 2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995.
62. Seagroves T, Johnson RS. Two HIFs may be better than one. Cancer Cell 1: 211-213, 2002 (Erratum in Cancer Cell 1: 403, 2002).
63. Hara S, Hamada J, Kobayashi C, Kondo Y, Imura N. Expression and characterization of hypoxia-inducible factor (HIF)-3a in human kidney: Suppression of HIF-mediated gene expression by HIF-3a. Biochem Biophys Res Commun 287: 808-813, 2001.
64. Gradin K, McGuire J, Wenger RH, et al. Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. Mol Cell Biol 16: 5221-5231, 1996.
65. Wood SM, Gleadle JM, Pugh CW, Hankinson O, Ratcliffe PJ. The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells. J Biol Chem 271: 15117-15123, 1996.
66. Jewell UR, Kviefikova I, Scheid A, Bauer C, Wenger RH, Gassmann M. Induction of HIF-1α in response to hypoxia is instantaneous. FASEB J 15: 1312-1314, 2001.
67. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J 20: 5197-5206, 2001.
68. 2-regulated prolyl hydroxylation. Science 292: 468-472, 2001.
69. 2 sensing. Science 292: 464-468, 2001.
70. Epstein ACR, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54, 2001.
71. Ivan M, Haberberger T, Gervasi DC, et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci USA 99: 13459-13464, 2003.
72. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337-1340, 2001.
73. Knowles HJ, Raval RR, Harris AL, Ratcliffe PJ. Effect of ascorbate on the activity of hypoxia inducible factor (HIF) in cancer cells. Cancer Res 63: 1764-1768, 2003.
74. Hirsilä M, Koivunen P, Günzler V, Kivirikko KI, Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 278: 30772-30780, 2003.
75. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999.
76. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nat Cell Biol 2: 423-427, 2000.
77. Salceda S, Caro J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272: 22642-22647, 1997.
78. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95: 7987-7992, 1998.
79. Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 32: 614-621, 2002.
80. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16: 1466-1471, 2002.
81. Dann CE 3rd, Bruick RK, Deisenhofer J. Structure of factor-inhibiting hypoxia-inducible factor 1: An asparaginyl hydroxylase involved in the hypoxic response pathway. Proc Natl Acad Sci USA 99: 15351-15356, 2002.
82. McNeill LA, Hewitson KS, Claridge TD, Seibel IF, Horsfall LE, Schofield CJ. Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. Biochem J 367: 571-575, 2002.
83. Huang J, Zhao Q, Mooney SM, Lee FS. Sequence determinants in hypoxia inducible factor-1α for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. J Biol Chem 277: 39792-39800, 2002.
84. Metzen E, Berchner-Pfannschmidt U, Stengel P, et al. Intracellular localisation of human HIF-1α hydroxylases: implications for oxygen sensing. J Cell Sci 116: 1319-1326, 2003.
85. Semenza GL, Jiang BH, Leung SW, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271: 32529-32537, 1996.
86. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nature Rev Drug Discov 2: 803-811, 2003.
87. Kling PJ, Dragsten PR, Roberts RA, et al. Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy. Br J Haematol 95: 241-248, 1996.
88. Wanner RM, Spielmann P, Stroka DM, et al. Epolones induce erythropoietin expression via hypoxia-inducible factor-1α activation. Blood 96: 1558-1565, 2000.
89. Ren X, Dorrington KL, Maxwell PH, Robbins PA. Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans. J Appl Physiol 89: 680-686, 2000.
90. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62: 4316-4324, 2002.
91. Koury ST, Koury MJ, Bondurant MC, Caro J, Graber SE. Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood 74: 645-651, 1989.
92. Kochling J, Curtin PT, Madan A. Regulation of human erythropoietin gene induction by upstream flanking sequences in transgenic mice. Br J Haematol 103: 960-968, 1998.
93. Rosenberger C, Mandriota S, Jurgensen JS, et al. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 13: 1721-1732, 2002.
94. Imagawa S, Izumi T, Miura Y. Positive and negative regulation of the erythropoietin gene. J Biol Chem 269: 9038-9044, 1994.
95. Imagawa S, Yamamoto M, Miura Y. Negative regulation of the erythropoietin gene expression by the GATA transcription factors. Blood 89: 1430-1439, 1997.
96. Tarumoto T, Imagawa S, Ohmine K, et al. K N(G)-monomethyl-L-arginine inhibits erythropoietin gene expression by stimulating GATA-2. Blood 96: 1716-1722, 2000.
97. Imagawa S, Tarumoto T, Suzuki N, et al. L-arginine rescues decreased erythropoietin gene expression by stimulating GATA-2 with L-NMMA. Kidney Int 61: 396-404, 2002.
98. Lee-Huang S, Lin JJ, Kung HF, Huang PL, Lee L, Huang PL. The human erythropoietin-encoding gene contains a CAAT box, TATA boxes and other transcriptional regulatory elements in its 5′ flanking region. Gene 128: 227-236, 1993.
99. La Ferla K, Reimann C, Jelkmann W, Hellwig-Bürgel T. Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-κB. FASEB J 16: 1811-1813, 2002.
100. Jelkmann W, Hellwig-Buergel T. Tumor necrosis factor p55 receptor (TNF-RI) mediates the in vitro inhibition of hepatic erythropoietin production. Exp Hematol 27: 224-228, 1999.
101. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 18: 555-559, 1998.
102. Imagawa S, Nakano Y, Obara N, et al. A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. FASEB J 17: 1742-1744, 2003.
103. Fandrey J, Huwiler A, Frede S, Pfeilschifter J, Jelkmann W. Distinct signaling pathways mediate phorbol-ester-induced and cytokine-induced inhibition of erythropoietin gene expression. Eur J Biochem 226: 335-340, 1994.
104. Fisher JW. Erythropoietin: Physiology and pharmacology update. Exp Biol Med 228: 1-14, 2003.
105. Koury MJ, Bondurant MC. The molecular mechanism of erythropoietin action. Eur J Biochem 210: 649-663, 1992.
106. De Maria R, Zeuner A, Eramo A, et al. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 401: 489-493, 1999.
107. Suzuki N, Suwabe N, Ohneda O, et al. Identification and characterization of 2 types of erythroid progenitors that express GATA-1 at distinct levels. Blood 102: 3575-3583, 2003.
108. Chiba T, Ikawa Y, Todokoro K. GATA-1 transactivates erythropoietin receptor gene, and erythropoietin receptor-mediated signals enhance GATA-1 gene expression. Nucleic Acids Res 19: 3843-3848, 1991.
109. Gregory T, Yu C, Ma A, Orkin SH, Blobel GA, Weiss MJ. GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood 94: 87-96, 1999.
110. Sato T, Maekawa T, Watanabe S, Tsuji K, Nakahata T. Erythroid progenitors differentiate and mature in response to endogenous erythropoietin. J Clin Invest 106: 263-270, 2000.
111. D'Andrea AD, Zon LI. Erythropoietin receptor. Subunit structure and activation. J Clin Invest 86: 681-687, 1990.
112. Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood 81: 2223-2236, 1993.
113. Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry 35: 1681-1691, 1996.
114. Syed RS, Reid SW, Li C, et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 395: 511-516, 1998.
115. Darling RJ, Kuchibhotla U, Glaesner W, Micanovic R, Witcher DR, Beals JM. Glycosylation of erythropoietin affects receptor binding kinetics: role of electrostatic interactions. Biochemistry 41: 14524-14531, 2002.
116. Cheetham JC, Smith DM, Aoki KH, et al. NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat Struct Biol 5: 861-866, 1998.
117. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 283: 987-990, 1999.
118. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 283: 990-993, 1999.
119. Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74: 227-236, 1993.
120. Tauchi T, Feng GS, Shen R, et al. Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways. J Biol Chem 270: 5631-5635, 1995.
121. Barber DL, Beattie BK, Mason JM, et al. A common epitope is shared by activated signal transducer and activator of transcription-5 (STAT5) and the phosphorylated erythropoietin receptor: implications for the docking model of STAT activation. Blood 97: 2230-2237, 2001.
122. Klingmuller U. The role of tyrosine phosphorylation in proliferation and maturation of erythroid progenitor cells-signals emanating from the erythropoietin receptor. Eur J Biochem 249: 637-647, 1997.
123. Yoshimura A, Misawa H. Physiology and function of the erythropoietin receptor. Curr Opin Hematol 5: 171-176, 1998.
124. Constantinescu SN, Huang LJ, Nam H, Lodish HF. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol Cell 7: 377-385, 2001.
125. Ohta M, Kawasaki N, Itoh S, Hayakawa T. Usefulness of glycopeptide mapping by liquid chromatography/mass spectrometry in comparability assessment of glycoprotein products. Biologicals 30: 235-244, 2002.
126. Zermati Y, Garrido C, Amsellem S, et al. Caspase activation is required for terminal erythroid differentiation. J Exp Med 193: 247-254, 2001.
127. Lin Y, Brown L, Hedley DW, Barber DL, Benchimol S. The death-promoting activity of p53 can be inhibited by distinct signaling pathways. Blood 100: 3990-4000, 2002 (Erratum in: Blood 101: 2114, 2003).
128. Oda A, Sawada KI. Signal transduction in primary cultured human erythroid cells. J Hematother Stem Cell Res 9: 417-423, 2000.
129. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 275: 29338-29347, 2000.
130. Yi T, Zhang J, Miura O, Ihle JN. Hematopoietic cell phosphatase associates with erythropoietin (Epo) receptor after Epo-induced receptor tyrosine phosphorylation: identification of potential binding sites. Blood 85: 87-95, 1995.
131. Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80: 729-738, 1995.
132. Verdier F, Walrafen P, Hubert N, et al. Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors. J Biol Chem 275: 18375-18381, 2000.
133. Supino-Rosin L, Yoshimura A, Altaratz H, Neumann D. A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation. Eur J Biochem 263: 410-419, 1999.
134. Kralovics R, Prchal JT. Genetic heterogeneity of primary familial and congenital polycythemia. Am J Hematol 68: 115-121, 2001.
135. Barbone FP, Johnson DL, Farrell FX, et al. New epoitin molecules and novel therapeutic approaches. Nephrol Dial Transplant 14 (Suppl 2): 80-84, 1999.
136. Moritz KM, Lim GB, Wintour EM. Developmental regulation of erythropoietin and erythropoiesis. Am J Physiol 273: R1829-R1844, 1997.
137. Masuda S, Nagao M, Sasaki R. Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Int J Hematol 70: 1-6, 1999.
138. Lappin TR, Maxwell AP, Johnston PG. EPO's alter ego: erythropoietin has multiple actions. Stem Cells 20: 485-492, 2002.
139. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 87: 5978-5982, 1990.
140. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 91: 3974-3978, 1994.
141. Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 126: 3597-3605, 1999.
142. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 55: 808-820, 1999.
143. Fenjves ES, Ochoa MS, Cabrera O, et al. Human, nonhuman primate, and rat pancreatic islets express erythropoietin receptors. Transplantation 75: 1356-1360, 2003.
144. Sawyer ST, Krantz SB, Sawada K. Receptors for erythropoietin in mouse and human erythroid cells and placenta. Blood 74: 103-109, 1989.
145. Digicaylioglu M, Bichet S, Marti HH, et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 92: 3717-3720, 1995.
146. Marti HH, Wenger RH, Rivas LA, et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 8: 666-676, 1996.
147. Li Y, Juul SE, Morris-Wiman JA, Calhoun DA, Christensen RD. Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses. Pediatr Res 40: 376-380, 1996.
148. Liu C, Shen K, Liu Z, Noguchi CT. Regulated human erythropoietin receptor expression in mouse brain. J Biol Chem 272: 32395-32400, 1997.
149. Jelkmann W. Effects of erythropoietin on brain function. Curr Pharmaceut Biotechnol 2004 (in press).
150. Suzuki N, Ohneda O, Takahashi S, et al. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 100: 2279-2288, 2002.
151. Berdel WE, Oberberg D, Reufi B, Thiel E. Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann Hematol 63: 5-8, 1991.
152. Mundt D, Berger MR, Bode G. Effect of recombinant human erythropoietin on the growth of human tumor cell lines in vitro. Micro-titertec-tetrazolium assay. Arzneimittelforschung 42: 92-95, 1992.
153. Rosti V, Pedrazzoli P, Ponchio L, et al. Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica 78: 208-212, 1993.
154. Westphal G, Niederberger E, Blum C, et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 88: 150-159, 2002.
155. Bauer E, Danhauser-Riedl S, De Riese W, et al. Effects of recombinant human erythropoietin on clonogenic growth of primary human tumor specimens in vivo. Onkologie 15: 254-258, 1992.
156. Kayser K, Gabius HJ. Analysis of expression of erythropoietin-binding sites in human lung carcinoma by the biotinylated ligand. Zentralbl Pathol 138: 266-270, 1992.
157. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61: 3561-3565, 2001.
158. Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 95: 969-981, 2002.
159. Arcasoy MO, Amin K, Karayal AF, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 82: 911-918, 2002.
160. Acs G, Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 162: 1789-1806, 2003.
161. Ohigashi T, Yoshioka K, Fisher JW. Autocrine regulation of erythropoietin gene expression in human hepatocellular carcinoma cells. Life Sci 58: 421-427, 1996.
162. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58: 647-657, 2000.
163. Yasuda Y, Fujita Y, Masuda S, et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 23: 1797-1805, 2002.
164. Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24: 1021-1029, 2003 (Erratum in: Carcinogenesis 24: 1567, 2003).
165. Yasuda Y, Musha T, Tanaka H, et al. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 84: 836-843, 2001.
166. Sytkowski AJ, Lunn ED, Davis KL, Feldman L, Siekman S. Human erythropoietin dimers with markedly enhanced in vivo activity. Proc Natl Acad Sci USA 95: 1184-1188, 1998.
167. Wrighton NC, Balasubramanian P, Barbone FP, et al. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nat Biotechnol 15: 1261-1265, 1997.
168. Qureshi SA, Kim RM, Konteatis Z, et al. Mimicry of erythropoietin by a nonpeptide molecule. Proc Natl Acad Sci USA 96: 12156-12161, 1999.
169. Goldberg J, Jin Q, Ambroise Y, et al. Erythropoietin mimetics derived from solution phase combinatorial libraries. J Am Chem Soc 124: 544-555, 2002.
170. Naffakh N, Danos O. Gene transfer for erythropoiesis enhancement. Mol Med Today 2: 343-348, 1996.
171. Warnecke C, Griethe W, Weidemann A, et al. Activation of the hypoxia-inducible factor pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J 17: 1186-1188, 2003.
172. Suzuki M, Hirasawa Y, Hirashima K, et al. Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease. Research Group for Clinical Assessment of rhEPO. Contrib Nephrol 76: 179-192, 1989.
173. Adamson JW, Eschbach JW. Treatment of the anemia of chronic renal failure with recombinant human erythropoietin. Annu Rev Med 41: 349-360, 1990.
174. Nomoto Y, Kawaguchi Y, Kubota M, et al. A multicenter study with once a week or once every two weeks high-dose subcutaneous administration of recombinant human erythropoietin in continuous ambulatory peritoneal dialysis. Perit Dial Int 14: 56-60, 1994.
175. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis 28: 53-61, 1996.
176. Silverberg D, Blum M, Peer G, Iaina A. Anemia during the predialysis period: A key to cardiac damage in renal failure. Nephron 80: 1-5, 1998.
177. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: 610-619, 1999.
178. Horl WH, Cavill I, MacDougall IC, Schaefer RM, Sunder-Plassmann G. How to diagnose and correct iron deficiency during r-huEPO therapy - a consensus report. Nephrol Dial Transplant 11: 246-250, 1996.
179. Kaneko Y, Miyazaki S, Hirasawa Y, Gejyo F, Suzuki M. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. Kidney Int 63: 1086-1093, 2003.
180. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998.
181. Jelkmann W. Use of recombinant human erythropoietin as an anti-anemic and performance enhancing drug. Curr Pharm Biotechnol 1: 11-31, 2000.
182. Bottomley A, Thomas R, van SK, Flechtner H, Djulbegovic B. Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? Lancet Oncol 3: 145-153, 2002.
183. Leyland-Jones B, BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4: 459-460, 2003.
184. Henke M, Laszing R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260, 2003.
185. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100: 2303-2320, 2002.
186. Masuda S, Nagao M, Takahata K, et al. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 268: 11208-11216, 1993.
187. Konishi Y, Chui DH, Hirose H, Kunishita T, Tabira T. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res 609: 29-35, 1993.
188. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95: 4635-4640, 1998.
189. Sadamoto Y, Igase K, Sakanaka M, et al. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 253: 26-32, 1998.
190. Wen TC, Sadamoto Y, Tanaka I, et al. Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression. J Neurosci Res 67: 795-803, 2002.
191. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97: 10526-10531, 2000.
192. Eid T, Brines M. Recombinant human erythropoietin for neuroprotection: what is the evidence? Clin Breast Cancer 3: S109-S115, 2002.
193. Juul SE. Nonerythropoietic roles of erythropoietin in the fetus and neonate. Clin Perinatol 27: 527-541, 2000.
194. Jumbe NL. Erythropoietic agents as neurotherapeutic agents: what barriers exist? Oncology 16: 91-107, 2002.
195. Cerami A, Brines M, Ghezzi P, Cerami C, Itri LM. Neuroprotective properties of epoetin alfa. Nephrol Dial Transplant 17: 8-12, 2002.
196. Ehrenreich H, Hasselblatt M, Dembrowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8: 495-505, 2002.
197. Bruick RK, McKnight SL. Oxygen sensing gets a second wind. Science 295: 807-808, 2002.